timontti
@timontti.bsky.social
Investing in Growth & Quantum 🐾 6 year CAGR: 33.1% 🐾 ENG/FIN 🐾 Fundamental & Technical analysis
Pinned
timontti
@timontti.bsky.social
· Nov 17
Game of Stonks:
- Build yourself good knowledge of the business.
- Estimate the Fair Value range (scenarios) for a longer period, e.g. 2-4 years ahead.
- Use manic-depressive Mr. Market to your advantage (fig. below).
- Concentrate on best cases, follow them daily.
- Time.
- Build yourself good knowledge of the business.
- Estimate the Fair Value range (scenarios) for a longer period, e.g. 2-4 years ahead.
- Use manic-depressive Mr. Market to your advantage (fig. below).
- Concentrate on best cases, follow them daily.
- Time.
Sijoitusteesi:
- Kvantti tulee AI:n rinnalle 2030-luvulle mentäessä.
- Kvantin TAM sama, kuin AI. 'Unknown' voi viedä reilusti ylikin.
- Teknis-taloudellinen merkitys: KVANTTI > AI
- Mag 7 rinnalle tulee ainakin 1-2 voittajaa Kvanttipuolelta. First Mover advantage keskeistä.
- Kvantti tulee AI:n rinnalle 2030-luvulle mentäessä.
- Kvantin TAM sama, kuin AI. 'Unknown' voi viedä reilusti ylikin.
- Teknis-taloudellinen merkitys: KVANTTI > AI
- Mag 7 rinnalle tulee ainakin 1-2 voittajaa Kvanttipuolelta. First Mover advantage keskeistä.
September 17, 2025 at 5:49 AM
Sijoitusteesi:
- Kvantti tulee AI:n rinnalle 2030-luvulle mentäessä.
- Kvantin TAM sama, kuin AI. 'Unknown' voi viedä reilusti ylikin.
- Teknis-taloudellinen merkitys: KVANTTI > AI
- Mag 7 rinnalle tulee ainakin 1-2 voittajaa Kvanttipuolelta. First Mover advantage keskeistä.
- Kvantti tulee AI:n rinnalle 2030-luvulle mentäessä.
- Kvantin TAM sama, kuin AI. 'Unknown' voi viedä reilusti ylikin.
- Teknis-taloudellinen merkitys: KVANTTI > AI
- Mag 7 rinnalle tulee ainakin 1-2 voittajaa Kvanttipuolelta. First Mover advantage keskeistä.
Reposted by timontti
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study reut.rs/4n96eM3
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study
Novo Nordisk said on Sunday its blockbuster weight-loss drug Wegovy cut the risk of heart attack, stroke or death by 57% versus Eli Lilly's rival medicines Mounjaro and Zepbound in a real-world comparison of overweight and obese patients with cardiovascular disease but not diabetes.
reut.rs
August 31, 2025 at 4:35 PM
Novo Nordisk's Wegovy cuts heart risk by 57% versus rival Lilly weight-loss drug in study reut.rs/4n96eM3
July 2, 2025 at 9:55 AM
#SNES 9 month trial:
"As a result of the collaboration, rodenticides have been eliminated from all 267 bait stations across common areas in UHills"
senestech.investorroom.com/2025-06-25-S...
"As a result of the collaboration, rodenticides have been eliminated from all 267 bait stations across common areas in UHills"
senestech.investorroom.com/2025-06-25-S...
SenesTech and Irvine Campus Housing Authority Conclude Successful Field Trial of Evolve™ Rat Birth Control at UC Irvine
A multi-pallet restocking order for continued deployment and expansion is being placed SURPRISE, Ariz., June 25, 2025 /PRNewswire/ -- SenesTech, Inc. (NASDAQ: SNES, "SenesTech" or the "Company"),...
senestech.investorroom.com
June 25, 2025 at 12:46 PM
#SNES 9 month trial:
"As a result of the collaboration, rodenticides have been eliminated from all 267 bait stations across common areas in UHills"
senestech.investorroom.com/2025-06-25-S...
"As a result of the collaboration, rodenticides have been eliminated from all 267 bait stations across common areas in UHills"
senestech.investorroom.com/2025-06-25-S...
#SNES evolve ratings have gathered some speed with great avg. reviews at Amazon.
Walmart.com has lesser reviews but great avg. score :)
Product is clearly working for consumers also 🔥
Walmart.com has lesser reviews but great avg. score :)
Product is clearly working for consumers also 🔥
June 19, 2025 at 4:25 PM
#SNES evolve ratings have gathered some speed with great avg. reviews at Amazon.
Walmart.com has lesser reviews but great avg. score :)
Product is clearly working for consumers also 🔥
Walmart.com has lesser reviews but great avg. score :)
Product is clearly working for consumers also 🔥
The person who puked in the test car did it for a bigger purpose
#seye 🇸🇪 🌞
www.inderes.fi/releases/sma...
#seye 🇸🇪 🌞
www.inderes.fi/releases/sma...
Smart Eye Launches First-Ever Driver Monitoring System with Alcohol Impairment Detection - Inderes
The upgraded AIS system also adds driver crash probability, real-time road condition alerts, and built-in cloud connectivity enabling fleet-wide OTA updates.Gothenburg, Sweden – June 11, 2025...
www.inderes.fi
June 11, 2025 at 7:04 PM
The person who puked in the test car did it for a bigger purpose
#seye 🇸🇪 🌞
www.inderes.fi/releases/sma...
#seye 🇸🇪 🌞
www.inderes.fi/releases/sma...
- HONOR will release 400 series phones on Fri 6th June.
- First with new AI Connect that allows for seamless connectivity with iOS devices.
- Elabs will have prox.sensor included (unannounced).
- HONOR's 10bn$ ecosystem plan.
- Friday could be significant day for #ELABS 🇳🇴
- First with new AI Connect that allows for seamless connectivity with iOS devices.
- Elabs will have prox.sensor included (unannounced).
- HONOR's 10bn$ ecosystem plan.
- Friday could be significant day for #ELABS 🇳🇴
June 4, 2025 at 4:37 PM
- HONOR will release 400 series phones on Fri 6th June.
- First with new AI Connect that allows for seamless connectivity with iOS devices.
- Elabs will have prox.sensor included (unannounced).
- HONOR's 10bn$ ecosystem plan.
- Friday could be significant day for #ELABS 🇳🇴
- First with new AI Connect that allows for seamless connectivity with iOS devices.
- Elabs will have prox.sensor included (unannounced).
- HONOR's 10bn$ ecosystem plan.
- Friday could be significant day for #ELABS 🇳🇴
Goldman estimates 17-20% CAGR growth for GLP-1 for the next 7-8 years. It's much about ramp-up of production. Medicines are already sufficiently effective. Next step is mainly to provide pills.
#NOVO #NVO
www.goldmansachs.com/insights/art...
#NOVO #NVO
www.goldmansachs.com/insights/art...
www.goldmansachs.com
May 27, 2025 at 10:50 AM
Goldman estimates 17-20% CAGR growth for GLP-1 for the next 7-8 years. It's much about ramp-up of production. Medicines are already sufficiently effective. Next step is mainly to provide pills.
#NOVO #NVO
www.goldmansachs.com/insights/art...
#NOVO #NVO
www.goldmansachs.com/insights/art...
Reposted by timontti
Oikein hyvä kevätkatsaus, sisältää myös positiivisia puolia #hesuli #sijoittaminen
areena.yle.fi/1-73085960
areena.yle.fi/1-73085960
Tuloskauden podi Q1/2025 | Pörssipäivä
Keskustelemassa pääanalyytikko Antti Saari OP:sta ja analyytikko Sauli Vilén Inderesiltä. Toimittajana Mikko Jylhä.
00:29 Trumpin tullisota
22:43 Tuloskausi Helsingissä
30:07 Sampo
38:05 Mandatum
43:...
areena.yle.fi
May 16, 2025 at 1:22 PM
Oikein hyvä kevätkatsaus, sisältää myös positiivisia puolia #hesuli #sijoittaminen
areena.yle.fi/1-73085960
areena.yle.fi/1-73085960